Global Migraine Drugs Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Veröffentlicht von: pbi
Veröffentlicht am: 15.03.2018 12:22
Rubrik: Urlaub & Reise

(Presseportal openBroadcast) - Global Migraine Drugs Market: By Drug Type, (Prophylactic, (Topiramate, Botulinum toxin), Abortive (Ergot Alkaloids, Triptans), By Route of Administration (Injectables, Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), By Region – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Market Outline: Global Migraine Drugs Market
A migraine is a primary headache disorder characterized by moderate to a severe headache. Typically migraine headaches affect half of the head and generally pulsatile. A migraine may last in a range of two hours to 72 hours. Other symptoms may include nausea, vomiting, sensitivity to light, smell and sound. Migraines may be preceded by an aura of sensory disturbances followed by severing an often onside headache. There are two types of migraine drugs are present in the market. Prophylactic drugs are used for the prevention of precedence of a migraine. Whereas, no particular migraine therapy drugs are available.

Market dynamics: Global Migraine Drugs Market
Global migraine drugs market is mainly driven by the increase in the prevalence of migraine worldwide. In addition, rise in R&D activities by the market players to develop new drugs and expected commercialization of the pipeline drugs are projected to bolster the market during the forecast period. Furthermore, growing awareness in population regarding early diagnosis and treatment of migraine coupled with the rise in healthcare expenditure globally projected to boost the global migraine drugs market share. However, availability of the generic drugs, other treatment options such as neuromodulators and others expected to impede the market global migraine drugs market over the forecast period.

A sample of this report is available upon request @

Market Scope: Global Migraine Drugs Market
Global migraine drugs market is segmented based on drug type, route of administration, distribution channel, and region
Based on drug type, market is segmented into
• Prophylactic
o Topiramate
o Botulinum toxin
• Abortive
o Ergot Alkaloids
o Triptans
Based on route of administration, market is segmented into
• Injectables
• Oral
Based on distribution channel, market is segmented into
• Hospital Pharmacies
• Retail Pharmacies
• Others
Based on region, market is segmented into
• North America
• Latin America
• Asia Pacific
• The Middle East and Africa
• Europe

Regional Analysis: Global Migraine Drugs Market
Geographically migraine drugs market is divided into five key regions, i.e. Europe, North America, Latin America, Asia- Pacific, and The Middle East & Africa. North America migraine drugs market is anticipated to grow at significant rates owing to the factors such as rise in the occurrence of migraine, greater healthcare expenditure, and recent product launches. Asia Pacific migraine drugs market is expected to have notable market growth over the forecast period owing to the growth in a number of people suffering from the migraine and growing awareness related to early diagnosis and treatment. China and India expected to have lucrative growth opportunities owing to the lifestyle changes and high prevalence rates of migraine in the countries

To view TOC of this report is available upon request @

Competition Assessment: Global Migraine Drugs Market
Some of the players in global migraine drugs market include
• AstraZeneca Plc. (U.K.)
• Allergan Plc. (U.S.)
• Pfizer, Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• GlaxoSmithKline plc (U.K)
• Eli Lilly & Co. (U.S.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• Valeant Pharmaceutical International, Inc. (Canada)
• Janssen Pharmaceutical Company (Johnson & Johnson) (U.S.)
• Endo International plc. (U.S.)
• Zosano Pharma Inc. (U.S.)
• Alder Biopharmaceuticals (U.S.)

Notable Market Developments: Global Migraine Drugs Market
• In April 2017, Amgen has expanded commercial collaboration with Novartis AG for investigational migraine drug erenumab, for treatment of migraine.

Need more information about this report @

Key Features of the Report:
• The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
• The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
• The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
• The report tracks recent innovations, key developments and startup’s details that are actively working in the market
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
• The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Get access to full summary @



Toll Free (US): +1-866-598-1553
Website @

Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.